Skip to main content
Premium Trial:

Request an Annual Quote

Natera, Mt. Sinai Partner on Genetic Carrier Screening Test

NEW YORK (GenomeWeb) – Natera and the Mount Sinai Genetic Testing Laboratory today announced a partnership to offer Natera's genetic carrier screening test.

The partnership allows Natera to broaden the test called Horizon to include 38 disorders, including an expanded panel designed specifically for Ashkenazi Jewish families, Natera CEO Matthew Rabinowitz said in a statement. The test also provides results for genetic disorders, such as cystic fibrosis, spinal muscular atrophy (SMA), and Tay-Sachs disease. Additionally, the expanded test increases detection rates for SMA over previous testing methods and refines risks for Fragile X syndrome, Natera said.

The Mount Sinai Genetic Testing Laboratory is part of the Icahn School of Medicine at Mount Sinai and offers screening tests for more than 100 disorders. Genetic screening is performed to determine whether an individual is a carrier for certain recessive genetic disorders.

"This is an important addition to Natera's product offering, as we are committed to expanding the breadth of genetic testing services that Natera delivers on a direct basis to our growing network of women's healthcare providers," Rabinowitz said.

Financial and other terms of the partnership were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.